InsiderSignalSign in

← Insider buys

KALV

KalVista Pharmaceuticals, Inc. · Healthcare

Insiders sold $6.8M of KalVista Pharmaceuticals, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$6.8MSold, 12 mo

$1.4BMarket cap

KALV over the last year

No insider buys filed in this year

KALV after insider buys

3 months after each buy, from the first price a copier could get.

−0.7%Average

−5.3 ptsVs S&P 500

5 of 13Higher

13 buys since 2017 with 3 months of prices.

Every filing

150 insider filings since 2017, newest first

Christopher Yea · Chief Development Officer

$905K−12.8%May 29

Christopher Yea · Chief Development Officer

$53K−0.8%May 27

Nicole Sweeny · Chief Commercial Officer

$40K−2.4%May 27

Paul K. Audhya · Chief Medical Officer

$60K−1.5%May 27

Benjamin L Palleiko · Chief Executive Officer

$293K−2.2%May 26

Nicole Sweeny · Chief Commercial Officer

$50K−3.2%May 26

Christopher Yea · Chief Development Officer

$63K−1.0%May 26

Paul K. Audhya · Chief Medical Officer

$72K−1.8%May 26

Brian Piekos · Chief Financial Officer

$40K−6.4%May 26

Christopher Yea · Chief Development Officer

Paul K. Audhya · Chief Medical Officer

$28K−1.0%May 19

Benjamin L Palleiko · CEO

Benjamin L Palleiko · CEO

$89K−1.0%May 13

Paul K. Audhya · Chief Medical Officer

$54K−2.0%Apr 20

Nicole Sweeny · Chief Commercial Officer

$38K−3.0%Apr 20

Brian Piekos · CFO

$38K−9.0%Apr 20

Benjamin L Palleiko · CEO

$193K−2.0%Apr 20

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$3.7M−4.0%Mar 27

Benjamin L Palleiko · CEO

$108K−1.0%Mar 10

Paul K. Audhya · Chief Medical Officer

$83K−4.0%Feb 24

Benjamin L Palleiko · CEO

$156K−2.0%Feb 24

Nicole Sweeny · Chief Commercial Officer

$62K−8.0%Feb 24

Brian Piekos · CFO

$28K−11.0%Feb 24

Christopher Yea · Chief Development Officer

$68K−2.0%Feb 24

Benjamin L Palleiko · CEO

$53K−1.0%Feb 13

Benjamin L Palleiko · CEO

$120K−2.0%Dec 9

Nicole Sweeny · Chief Commercial Officer

$51K−9.0%Dec 4

Brian Piekos · CFO

$60K−30.0%Nov 26

Paul K. Audhya · Chief Medical Officer

$71K−4.0%Nov 26

Benjamin L Palleiko · CEO

$147K−3.0%Nov 26

Christopher Yea · Chief Development Officer

$58K−2.0%Nov 26

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.5M+3.0%Feb 14

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$967K+2.0%Feb 11

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$622K+1.0%Feb 3

Benjamin L Palleiko · CEO

$133K−5.0%Nov 19

Paul K. Audhya · Chief Medical Officer

$75K−8.0%Nov 19

Christopher Yea · Chief Development Officer

$67K−7.0%Nov 19

Benjamin L Palleiko · CEO

$90K−3.0%Sep 10

Paul K. Audhya · Chief Medical Officer

$26K−2.0%Aug 26

Paul K. Audhya · Chief Medical Officer

$96K−9.0%Aug 21

Benjamin L Palleiko · CEO

$171K−6.0%Aug 21

Christopher Yea · Chief Development Officer

$85K−8.0%Aug 21

Benjamin L Palleiko · CEO

$86K−3.0%Jun 10

Paul K. Audhya · Chief Medical Officer

$155K−16.0%May 21

Benjamin L Palleiko · CEO

$258K−9.0%May 21

Edward P. Feener · Chief Scientific Officer

$95K−10.0%May 21

Christopher Yea · Chief Development Officer

$137K−13.0%May 21

Benjamin L Palleiko · CFO, CBO

$322K−11.0%Feb 21

Paul K. Audhya · Chief Medical Officer

$202K−21.0%Feb 21

About KalVista Pharmaceuticals, Inc.

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.